awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33439342-8C2A7678-4452-4311-A6E6-0A651DD408FD
Q33439342-8C2A7678-4452-4311-A6E6-0A651DD408FD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33439342-8C2A7678-4452-4311-A6E6-0A651DD408FD
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.
P2860
Q33439342-8C2A7678-4452-4311-A6E6-0A651DD408FD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33439342-8C2A7678-4452-4311-A6E6-0A651DD408FD
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e65d3a09a8cbe21d4ce84c82da2062caa1b5707d
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer